Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)

Status Recruiting

Clinical Trial Summary

An open-label, single-arm, phase II clinical study of anti-PD-1 antibody GB226 in treatment of recurrent or refractory B-cell non-Hodgkin's lymphoma (B-NHL)

Clinical Trial Description

GB226, 3mg/kg/time, is intravenously infused once every two weeks until disease progression, intolerable toxicity or study withdrawal decided by the investigator/subject. It is expected that each subject will be followed for 2 years. Subjects receiving GB226 treatment will be followed once every 2 weeks to the end of this study. If the patients terminate the treatment and their imaging assessment shows no progressive disease (PD), they should be followed once every 6 weeks until progressive disease (imaging evaluation). If the patients have progressive disease (imaging assessment), they should be followed every 3 months until the end of this study or premature withdrawal from the study. Relevant tests and evaluation should be completed at each visit according to standard of care. The follow-up visits can be performed by telephone. During the study, subjects must complete one imaging test and efficacy evaluation every 6 weeks until disease progression. Moreover, patients should be closely monitored for adverse events from subject enrollment to 30 days after the last dosing ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03639181
Study type	Interventional
Source	Genor Biopharma Co., Ltd.
Contact	Shawn Yu, Master
Phone	86-010-65260820
Email	shawn.yu@genorbio.com
Status	Recruiting
Phase	Phase 2
Start date	October 15, 2018
Completion date	December 30, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00588094` - Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL	Phase 2
Not yet recruiting	`NCT05091541` - A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma	Phase 1/Phase 2
Recruiting	`NCT06104553` - A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma	Phase 1/Phase 2
Terminated	`NCT01352312` - Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma	Phase 1
Not yet recruiting	`NCT05771883` - A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide	Phase 1/Phase 2
Not yet recruiting	`NCT06314828` - A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL	Phase 1
Enrolling by invitation	`NCT05332054` - Long-Term Follow-up Study
Suspended	`NCT04697290` - CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.	Early Phase 1
Completed	`NCT02564744` - Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL	Phase 2
Recruiting	`NCT05453669` - Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL	Phase 1
Recruiting	`NCT05190068` - HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma	Phase 1
Suspended	`NCT04746131` - Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)	Phase 1
Active, not recruiting	`NCT00927797` - Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)	Phase 2
Recruiting	`NCT05436223` - Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma	Phase 2
Completed	`NCT00457782` - A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma	Phase 1
Not yet recruiting	`NCT03105596` - Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)	Phase 2